View Post

RPS-Optimized Checkpoint Inhibition Bolsters pCR in Patients With Select Rare Breast Cancers

In In The News by Barbara Jacoby

By: Courtney Flaherty From: onclive.com Patients with select rare breast cancer subtypes, such as metaplastic and lobular histologies, achieved high pathologic complete response (pCR) rates with response-predictive subtype (RPS)–optimized treatment with a checkpoint inhibitor, although patients with rare breast cancers overall experienced shorter event-free survival (EFS) vs those with no special type (NST), according to data from an analysis of …